2024-08-012025-07-312025-07-31false04952479PHARMARTEL LIMITED2026-07-31falseiso4217:GBPxbrli:pure049524792024-07-31049524792025-07-31049524792024-08-012025-07-31049524792023-07-31049524792024-07-31049524792023-08-012024-07-3104952479bus:SmallEntities2024-08-012025-07-3104952479bus:AuditExempt-NoAccountantsReport2024-08-012025-07-3104952479bus:FullAccounts2024-08-012025-07-3104952479bus:PrivateLimitedCompanyLtd2024-08-012025-07-3104952479core:WithinOneYear2025-07-3104952479core:AfterOneYear2025-07-3104952479core:WithinOneYear2024-07-3104952479core:AfterOneYear2024-07-3104952479core:ShareCapital2025-07-3104952479core:SharePremium2025-07-3104952479core:RevaluationReserve2025-07-3104952479core:OtherReservesSubtotal2025-07-3104952479core:RetainedEarningsAccumulatedLosses2025-07-3104952479core:ShareCapital2024-07-3104952479core:SharePremium2024-07-3104952479core:RevaluationReserve2024-07-3104952479core:OtherReservesSubtotal2024-07-3104952479core:RetainedEarningsAccumulatedLosses2024-07-3104952479core:LandBuildings2025-07-3104952479core:PlantMachinery2025-07-3104952479core:Vehicles2025-07-3104952479core:FurnitureFittings2025-07-3104952479core:OfficeEquipment2025-07-3104952479core:NetGoodwill2025-07-3104952479core:IntangibleAssetsOtherThanGoodwill2025-07-3104952479core:ListedExchangeTraded2025-07-3104952479core:UnlistedNon-exchangeTraded2025-07-3104952479core:LandBuildings2024-07-3104952479core:PlantMachinery2024-07-3104952479core:Vehicles2024-07-3104952479core:FurnitureFittings2024-07-3104952479core:OfficeEquipment2024-07-3104952479core:NetGoodwill2024-07-3104952479core:IntangibleAssetsOtherThanGoodwill2024-07-3104952479core:ListedExchangeTraded2024-07-3104952479core:UnlistedNon-exchangeTraded2024-07-3104952479core:LandBuildings2024-08-012025-07-3104952479core:PlantMachinery2024-08-012025-07-3104952479core:Vehicles2024-08-012025-07-3104952479core:FurnitureFittings2024-08-012025-07-3104952479core:OfficeEquipment2024-08-012025-07-3104952479core:NetGoodwill2024-08-012025-07-3104952479core:IntangibleAssetsOtherThanGoodwill2024-08-012025-07-3104952479core:ListedExchangeTraded2024-08-012025-07-3104952479core:UnlistedNon-exchangeTraded2024-08-012025-07-3104952479core:MoreThanFiveYears2024-08-012025-07-3104952479core:Non-currentFinancialInstruments2025-07-3104952479core:Non-currentFinancialInstruments2024-07-3104952479dpl:CostSales2024-08-012025-07-3104952479dpl:DistributionCosts2024-08-012025-07-3104952479core:LandBuildings2024-08-012025-07-3104952479core:PlantMachinery2024-08-012025-07-3104952479core:Vehicles2024-08-012025-07-3104952479core:FurnitureFittings2024-08-012025-07-3104952479core:OfficeEquipment2024-08-012025-07-3104952479dpl:AdministrativeExpenses2024-08-012025-07-3104952479core:NetGoodwill2024-08-012025-07-3104952479core:IntangibleAssetsOtherThanGoodwill2024-08-012025-07-3104952479dpl:GroupUndertakings2024-08-012025-07-3104952479dpl:ParticipatingInterests2024-08-012025-07-3104952479dpl:GroupUndertakingscore:ListedExchangeTraded2024-08-012025-07-3104952479core:ListedExchangeTraded2024-08-012025-07-3104952479dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-08-012025-07-3104952479core:UnlistedNon-exchangeTraded2024-08-012025-07-3104952479dpl:CostSales2023-08-012024-07-3104952479dpl:DistributionCosts2023-08-012024-07-3104952479core:LandBuildings2023-08-012024-07-3104952479core:PlantMachinery2023-08-012024-07-3104952479core:Vehicles2023-08-012024-07-3104952479core:FurnitureFittings2023-08-012024-07-3104952479core:OfficeEquipment2023-08-012024-07-3104952479dpl:AdministrativeExpenses2023-08-012024-07-3104952479core:NetGoodwill2023-08-012024-07-3104952479core:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3104952479dpl:GroupUndertakings2023-08-012024-07-3104952479dpl:ParticipatingInterests2023-08-012024-07-3104952479dpl:GroupUndertakingscore:ListedExchangeTraded2023-08-012024-07-3104952479core:ListedExchangeTraded2023-08-012024-07-3104952479dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-08-012024-07-3104952479core:UnlistedNon-exchangeTraded2023-08-012024-07-3104952479core:NetGoodwill2025-07-3104952479core:IntangibleAssetsOtherThanGoodwill2025-07-3104952479core:LandBuildings2025-07-3104952479core:PlantMachinery2025-07-3104952479core:Vehicles2025-07-3104952479core:FurnitureFittings2025-07-3104952479core:OfficeEquipment2025-07-3104952479core:AfterOneYear2025-07-3104952479core:WithinOneYear2025-07-3104952479core:ListedExchangeTraded2025-07-3104952479core:UnlistedNon-exchangeTraded2025-07-3104952479core:ShareCapital2025-07-3104952479core:SharePremium2025-07-3104952479core:RevaluationReserve2025-07-3104952479core:OtherReservesSubtotal2025-07-3104952479core:RetainedEarningsAccumulatedLosses2025-07-3104952479core:NetGoodwill2024-07-3104952479core:IntangibleAssetsOtherThanGoodwill2024-07-3104952479core:LandBuildings2024-07-3104952479core:PlantMachinery2024-07-3104952479core:Vehicles2024-07-3104952479core:FurnitureFittings2024-07-3104952479core:OfficeEquipment2024-07-3104952479core:AfterOneYear2024-07-3104952479core:WithinOneYear2024-07-3104952479core:ListedExchangeTraded2024-07-3104952479core:UnlistedNon-exchangeTraded2024-07-3104952479core:ShareCapital2024-07-3104952479core:SharePremium2024-07-3104952479core:RevaluationReserve2024-07-3104952479core:OtherReservesSubtotal2024-07-3104952479core:RetainedEarningsAccumulatedLosses2024-07-3104952479core:NetGoodwill2023-07-3104952479core:IntangibleAssetsOtherThanGoodwill2023-07-3104952479core:LandBuildings2023-07-3104952479core:PlantMachinery2023-07-3104952479core:Vehicles2023-07-3104952479core:FurnitureFittings2023-07-3104952479core:OfficeEquipment2023-07-3104952479core:AfterOneYear2023-07-3104952479core:WithinOneYear2023-07-3104952479core:ListedExchangeTraded2023-07-3104952479core:UnlistedNon-exchangeTraded2023-07-3104952479core:ShareCapital2023-07-3104952479core:SharePremium2023-07-3104952479core:RevaluationReserve2023-07-3104952479core:OtherReservesSubtotal2023-07-3104952479core:RetainedEarningsAccumulatedLosses2023-07-3104952479core:AfterOneYear2024-08-012025-07-3104952479core:WithinOneYear2024-08-012025-07-3104952479core:Non-currentFinancialInstrumentscore:CostValuation2024-08-012025-07-3104952479core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-012025-07-3104952479core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-012025-07-3104952479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-012025-07-3104952479core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-012025-07-3104952479core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-012025-07-3104952479core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-012025-07-3104952479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-012025-07-3104952479core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-012025-07-3104952479core:Non-currentFinancialInstrumentscore:CostValuation2025-07-3104952479core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-07-3104952479core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-07-3104952479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-07-3104952479core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-07-3104952479core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-07-3104952479core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-07-3104952479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-07-3104952479core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-07-3104952479core:Non-currentFinancialInstrumentscore:CostValuation2024-07-3104952479core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-07-3104952479core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-07-3104952479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-07-3104952479core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-07-3104952479core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-07-3104952479core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-07-3104952479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-07-3104952479core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-07-3104952479bus:Director12024-08-012025-07-3104952479core:FurnitureFittingsToolsEquipment2024-07-3104952479core:FurnitureFittingsToolsEquipment2024-08-012025-07-3104952479core:FurnitureFittingsToolsEquipment2025-07-31

PHARMARTEL LIMITED

Registered Number
04952479
(England and Wales)

Unaudited Financial Statements for the Year ended
31 July 2025

PHARMARTEL LIMITED
Company Information
for the year from 1 August 2024 to 31 July 2025

Director

VARAVIPOUR, Ehsan

Company Secretary

VARAVIPOUR, Ehsan

Registered Address

2nd Floor Grove House
55 Lowlands Road
Harrow
HA1 3AW

Registered Number

04952479 (England and Wales)
PHARMARTEL LIMITED
Balance Sheet as at
31 July 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets415,14811,591
15,14811,591
Current assets
Stocks581,85080,125
Debtors6385,188299,444
Cash at bank and on hand44,08433,696
511,122413,265
Creditors amounts falling due within one year7(274,304)(266,586)
Net current assets (liabilities)236,818146,679
Total assets less current liabilities251,966158,270
Creditors amounts falling due after one year8(12,801)(30,554)
Net assets239,165127,716
Capital and reserves
Called up share capital200200
Profit and loss account238,965127,516
Shareholders' funds239,165127,716
The financial statements were approved and authorised for issue by the Director on 31 July 2026, and are signed on its behalf by:
VARAVIPOUR, Ehsan
Director
Registered Company No. 04952479
PHARMARTEL LIMITED
Notes to the Financial Statements
for the year ended 31 July 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Intangible assets
Goodwill being the amount paid in connection with the acquisition of the business in 2004, is being amortised evenly over its estimated useful life of 10 years.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Fixtures and fittings15
Vehicles25
Office Equipment25
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20252024
Average number of employees during the year56
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 August 24415,439415,439
At 31 July 25415,439415,439
Amortisation and impairment
At 01 August 24415,439415,439
At 31 July 25415,439415,439
Net book value
At 31 July 25--
At 31 July 24--
4.Tangible fixed assets

Vehicles

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 August 244,400122,88812,646139,934
Additions4,999789-5,788
At 31 July 259,399123,67712,646145,722
Depreciation and impairment
At 01 August 241,169115,35711,817128,343
Charge for year8071,2172072,231
At 31 July 251,976116,57412,024130,574
Net book value
At 31 July 257,4237,10362215,148
At 31 July 243,2317,53182911,591
5.Stocks

2025

2024

££
Raw materials and consumables81,85080,125
Total81,85080,125
6.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables83,85164,766
Amounts owed by group undertakings186,416106,340
Other debtors93,147116,433
Prepayments and accrued income21,77411,905
Total385,188299,444
7.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables187,005204,309
Bank borrowings and overdrafts10,00010,000
Taxation and social security38,75416,618
Payments received on account31,03125,564
Other creditors7,5146,436
Accrued liabilities and deferred income-3,659
Total274,304266,586
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
8.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts12,80130,554
Total12,80130,554